ストックスクリーナーアプリを入手
0.6043
1.90%
-0.0117
アフターアワーズ：
.58
-0.0243
-4.02%
Galmed Pharmaceuticals Ltd (GLMD) 最新ニュース
GLMD Should I Buy - Intellectia AI
GLMD Q4 2025 Earnings: EPS Misses Estimates by Significant MarginEBITDA Analysis - newsline.com
Galmed to acquire Colospan for USD 4.5M - Medical Buyer
Galmed to acquire medical device firm Colospan for $4.5M By Investing.com - Investing.com Australia
Galmed to Acquire Colospan in Deal Expanding GI Medtech Platform - citybiz
Galmed Pharmaceuticals to Acquire Colospan, targeting $6B GI market - grafa.com
Incyte, Galmed, and Johnson & Johnson Announce Acquisitions Totaling $3 Billion - geneonline.com
Galmed to acquire medical device firm Colospan for $4.5M - Investing.com UK
Galmed Pharmaceuticals to Acquire Colospan and Commit $6 Million to European Expansion - TipRanks
Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market - The AI Journal
Galmed Pharmaceuticals (NASDAQ: GLMD) files amendment adding auditor consent - Stock Titan
Galmed (NASDAQ: GLMD) registers 7.5M shares; agrees to buy Colospan - Stock Titan
[6-K] Galmed Pharmaceuticals Ltd. Current Report (Foreign Issuer) | GLMD SEC FilingForm 6-K - Stock Titan
Press Release: Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market - Moomoo
Galmed’s $6B bet on Colospan device to ease life after colorectal surgery - Stock Titan
GLMD News | GALMED PHARMACEUTICALS LTD (NASDAQ:GLMD) - ChartMill
Galmed and Tissue Dynamics Reveal New Metabolic Target for Cardiac Fibrosis With Aramchol Combo - TipRanks
Galmed, Tissue Dynamics report preclinical cardiac fibrosis data By Investing.com - Investing.com South Africa
Galmed (GLMD) and Tissue Dynamics show fourfold fibrosis cut in human heart organoids - Stock Titan
Galmed, Tissue Dynamics report preclinical cardiac fibrosis data - Investing.com
Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis - PR Newswire
Galmed Pharmaceuticals (GLMD) Surges 9.35% as Shares Test Key ResistanceOutside Reversal - The Legal Advocate
Galmed Pharmaceuticals (GLMD) Surges 9.5%: Testing Key Resistance at $0.71Momentum Trade - The Legal Advocate
GLMD Stock Price, Quote & Chart | GALMED PHARMACEUTICALS LTD (NASDAQ:GLMD) - ChartMill
GLMD Q1'26 Earnings: EPS estimate is (0.38) USD - TradingView
Galmed Pharmaceuticals Ltd expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Number of shareholders of Galmed Pharmaceuticals Ltd. – FWB:GPH - TradingView
Galmed Pharmaceuticals Ltd.Ordinary Shares (NQ: GLMD - FinancialContent
TradingKey - TradingKey
Galmed Reports Fivefold Bioavailability Boost with New Aramchol Meglumine Oral Formulation - TipRanks
Galmed reports improved bioavailability in Aramchol study - Investing.com
Galmed reports improved bioavailability in Aramchol study By Investing.com - Investing.com Australia
Aramchol PK study shows fivefold exposure gain, Galmed (NASDAQ: GLMD) says - Stock Titan
Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg - PR Newswire
Tissue Dynamics, Galmed partner on cardiac fibrosis model By Investing.com - Investing.com Australia
Tissue Dynamics and Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) announce a strategic collaboration to jointly develop a chronic cardiac fibrosis research platform focused on human disease models. - Bitget
Galmed (NASDAQ: GLMD) teams with Tissue Dynamics on chronic cardiac fibrosis platform - Stock Titan
Tissue Dynamics, Galmed partner on cardiac fibrosis model - Investing.com
Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics - PR Newswire
GLMD (Galmed Pharmaceuticals Ltd. Ordinary Shares) posts wider than expected Q4 2025 loss, shares dip nearly one percent.Meet Estimates - Xã Thanh Hà
Shmuel Nir Net Worth (2026) - GuruFocus
Amir Poshinski Net Worth (2026) - GuruFocus
Brueck Liat Nissimov Net Worth (2026) - GuruFocus
Doron Leib Cohen Net Worth (2026) - GuruFocus
Allen Baharaff Net Worth (2026) - GuruFocus
Yohai Stenzler Net Worth (2026) - GuruFocus
Guy Nehemya Net Worth (2026) - GuruFocus
Galmed Pharmaceuticals (GLMD) Stock: Beginner's Guide (Smart Money Outflows) 2026-04-15Fast Moving Stocks - Cổng thông tin điện tử Tỉnh Sơn La
Galmed collaborates with Tel Aviv University to evaluate targeted therapy for metastatic brain cancers - BioSpectrum Asia
Galmed Pharmaceuticals Ltd. and Ramot At Tel Aviv University Enter Research Collaboration Agreement - marketscreener.com
Galmed partners with Tel Aviv University on brain cancer therapy By Investing.com - Investing.com Australia
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):